AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03853239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal ventilation crossover face mask ventilation
Description: Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
Study NCT04719143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Subjects receive 6-8 CBT-I sessions in an individual format.
Study NCT01326182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAADRE
Description: Group-based intervention combining asthma education and CBT for depressive symptoms
Study NCT01326182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MAAS
Description: Group-based intervention including asthma education and education regarding general child health
Study NCT01791348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: d2 test of attention
Study NCT04540146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
Study NCT04492462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formal Physical Therapy
Description: Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
Study NCT04492462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed Physical Therapy
Description: Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
Study NCT01969487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative warm-up on simulator
Study NCT02670824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Single and multiple intravenous (IV) doses of CN-105
Study NCT02670824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT00683163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTH(1-84)
Description: 1.4 mg injected subcutaneously (in the abdomen) daily
Study NCT00683163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: 150mg by mouth once monthly
Study NCT00683163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection
Description: Daily injections as placebo for PTS 1-84
Study NCT00683163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: Monthly pills as placebo for oral ibandronate
Study NCT02596477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer
Study NCT02596477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Study NCT01724840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GraftJacket
Description: Interposition with GraftJacket
Study NCT01724840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon Interposition
Description: Tendon Interposition with the FCR tendon
Study NCT02322125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk
Description: Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
Study NCT01199588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® Low Dose
Description: Weekly, topical application of Nexagon® low dose used with compression dressings.
Study NCT01199588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® High Dose
Description: Weekly, topical application of Nexagon® high dose used with compression dressings.
Study NCT01199588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nexagon® Vehicle
Description: Weekly, topical application of Nexagon® Vehicle used with compression dressings.
Study NCT00257166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone oral capsules
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
Study NCT00257166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral capsules
Description: Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
Study NCT01887236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step physical activity program
Description: Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
Study NCT01887236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stability Ball Program
Description: Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
Study NCT02768337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Study NCT02768337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT02768337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2 Gy targeted radiotherapy
Study NCT02768337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4 Gy targeted radiotherapy
Study NCT02280395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUT058-60
Description: Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
Study NCT02280395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline for irrigation
Description: Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
Study NCT02386436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
Study NCT02386436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
Study NCT00095875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00095875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00095875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00095875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT03278184 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham motor cortex
Description: the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
Study NCT03278184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active prefrontal cortex stimulation
Description: the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
Study NCT03278184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active motor cortex stimulation
Description: the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
Study NCT01490099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
Study NCT01490099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
Study NCT04024033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pine cone extract
Description: pine cone extract capsule
Study NCT04024033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study NCT05151081 — intervention group
Intervention type: OTHER
Intervention: basicly
Description: Do not repeat information already included in arm/group descriptions.
Study NCT02681536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Study NCT02681536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills
Study NCT02681536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMG
Study NCT00929175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active CPAP
Description: auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
Study NCT00929175 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-CPAP
Description: The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
Study NCT02227732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: New Indwelling Pleural Catheter
Description: Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
Study NCT04272840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Education
Description: Educational materials layering Glycemic Index education onto Canada's Food Guide and Diabetes Canada recommendations.
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk 4.0
Description: Silk suture 4.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PG 910 4.0
Description: PG 910 4.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PP 4.0
Description: PP 4.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk 5.0
Description: Silk 5.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PG910 5.0
Description: PG910 5.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PP 5.0
Description: PP 5.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APG 5.0
Description: APG 5.0
Study NCT03410433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePTFE 5.0
Description: ePTFE 5.0
Study NCT03075800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)
Description: The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
Study NCT03426371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-140
Description: KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT03426371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT01164774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
Study NCT01164774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace
Description: Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
Study NCT01593293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PemCarbo
Description: Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
Study NCT01593293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pem only
Description: Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
Study NCT00885703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally.
Study NCT00885703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally.
Study NCT00885703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
Study NCT00900458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise training
Description: aerobic exercise training (cycling)
Study NCT00900458 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise training
Description: aerobic exercise training (cycling)
Study NCT01417715 — intervention group
Intervention type: DEVICE
Intervention: Endomicroscopy
Description: Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
Study NCT00645814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: 80 mg at Week 0 and 40 mg eow through Week 11
Study NCT00645814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg at Week 0 and 40 mg eow through Week 11
Study NCT00645814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg at Week 0 and 40 mg weekly through Week 11
Study NCT03960775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
Study NCT03960775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline infusion during same time period.
Study NCT03104699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: Anti-PD-1 Monoclonal Antibody
Study NCT03529721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zumba dance fitness
Description: females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
Study NCT03529721 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non zumba dance
Description: participants in this group will be doing their normal daily activities throughout the 8-week period.
Study NCT02452905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Study NCT02452905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Nitazoxanide)
Study NCT01473238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation form
Description: A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
Study NCT01473238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation form
Description: A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
Study NCT02369848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty System
Study NCT01449461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets and capsules.
Study NCT03181932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin inhalation powder
Description: 100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
Study NCT03181932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder
Description: 100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
Study NCT03181932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin inhalation powder
Description: In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
Study NCT02928965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
Study NCT02928965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with appearance of over - encapsulated minocycline